Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5401 - Baseline neutrophil-to-lymphocyte ratio and its values monitored over time is associated with outcome of metastatic melanoma patients treated with immunotherapy


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Melanoma


Iwona Lugowska


Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377


I. Lugowska1, B. Cybulska-Stopa2, P. Jagodzinska-Mucha1, P. Teterycz1, H. Koseła-Paterczyk1, K. Kozak1, K. Szamotulska3, K. Roman2, T. Switaj1, M. Ziobro2, P. Rutkowski1

Author affiliations

  • 1 Soft Tissue/bone Sarcoma And Melanoma, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, 02-781 - Warsaw/PL
  • 2 Systemic Neoplasm, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, 310115781 - Krakow/PL
  • 3 Biostatistics, Institute of Mother and Child, 02495 - Warszawa/PL


Abstract 5401


Neutrophil-to-lymphocyte ratio (N/L) was shown to be prognostic in several solid malignancies. There are limited data about changes of N/L ratios during immunotherapy. The aim of the study was to asses a clinical value of this ratio and its association with tumour response in patients with advanced melanoma.


Between June 2011 and March 2017, 308 patients with metastatic/unresectable melanoma were included to the analysis. Patients age was 58.4±17.3 years (mean), 43 cases had brain metastases. BRAF mutation was present in 107 cases, and 98 patients with positive mutation received targeted therapies with BRAF+/- MEK followed by ipilumumab and/or anti-PD1 therapy. Patients with BRAF negative mutation received immunotherapy (pembrolizumab or nivolumab with/without ipilimumab). In all patients the N/L ratio was assessed at the baseline and monitored during treatment until disease progression or last observation. The cut off for ratio N/L was set at 3. Logistic GEE and Kaplan-Meier survival probability estimation were used for analysis.


N/L ratio ≥3 at baseline was significantly associated with poorer overall survival (OS) (p 


Our results confirm the usefulness of N/L ratio as a prognostic and predictive marker in patients with metastatic melanoma, and monitoring of the N/L ratio over immunotherapy may be helpful for assessment of the disease progression, response, as well as pseudoprogression, thus likely contributes to an optimization of treatment and resource allocation in patients with metastatic melanoma.

Clinical trial identification

not applicable

Legal entity responsible for the study

Maria Sklodowska-Curie Institute and Oncology Center, Warsaw, Poland




B. Cybulska-Stopa, H. Koseła-Paterczyk: Personal fees for lectures from Novartis, Roche, Bristol-Myers Squibb, MSD. K. Kozak: Personal fees for lectures from Novartis, Roche, Bristol-Myers Squibb and MSD. P. Rutkowski: Reports personal fees from Novartis, Bristol-Myers Squibb, Roche, MSD, GSK, Amgen - lecture honoraria and membership of Advisory outside the submitted work. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.